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Toll-like receptors (TLRs) form part of the host innate
immune system, in which they act as sensors of microbial and
endogenous danger signals. Upon TLR activation, the intracel-
lular Toll/interleukin-1 receptor domains of TLR dimers initi-
ate oligomerization of a multiprotein signaling platform com-
prising myeloid differentiation primary response 88 (MyD88)
and members of the interleukin-1 receptor–associated kinase
(IRAK) family. Formation of this myddosome complex initiates
signal transduction pathways, leading to the activation of tran-
scription factors and the production of inflammatory cytokines.
To date, little is known about the assembly and disassembly of
themyddosome and about themechanisms bywhich these com-
plexes mediate multiple downstream signaling pathways. Here,
we isolated myddosome complexes from whole-cell lysates of
TLR-activated primary mouse macrophages and from IRAK
reporter macrophages to examine the kinetics of myddosome
assembly and disassembly. Using a selective inhibitor of
IRAK4’s kinase activity, we found that whereas TLR cytokine
responseswere ablated,myddosome formationwas stabilized in
the absence of IRAK4’s kinase activity. Of note, IRAK4 inhibi-
tion had only a minimal effect on NF-B andmitogen-activated
protein kinase (MAPK) signaling. In summary, our results indi-
cate that IRAK4 has a critical scaffold function in myddosome
formation and that its kinase activity is dispensable for myddo-
some assembly and activation of the NF-B and MAPK path-
ways but is essential for MyD88-dependent production of
inflammatory cytokines. Our findings suggest that the scaffold
function of IRAK4 may be an attractive target for treating
inflammatory and autoimmune diseases.
Families of highly conserved pattern recognition receptors
expressed primarily by specialized immune cells, such as
macrophages and dendritic cells, have evolved to recognize
microbial and endogenous danger signals to activate an innate
immune response (1). This response mediates a rapid and con-
trolled acute inflammatory environment aimed at eliminating
invading microorganisms via production of inflammatory
mediators such as cytokines, chemokines, and interferons (2).
The Toll-like receptors (TLRs)4 are an important family of pat-
tern recognition receptors comprising 10 TLRs in humans and
12 expressed in mice (3). Whereas TLRs expressed on the cell
surface typically recognize outer membrane components of
bacteria, intracellular TLRs localizedwithin acidified endolyso-
somal compartments detect microbial nucleic acids. TLRs
exhibit a three-domain structure comprising a ligand recogni-
tion domain consisting of folded leucine-rich repeats at the N
terminus, a central transmembrane-anchoring region, and
a C-terminal cytoplasmic Toll/interleukin-1 (IL-1) receptor
(TIR) domain that enables coupling of the TLRs to cytosolic
TIR domain–containing adaptor proteins for triggering down-
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stream signal transduction (4). Upon activation, TLRs initiate
two main pathways that are predominantly dependent on
the adaptors, myeloid differentiation primary response 88
(MyD88) and TIR domain–containing adapter–inducing
interferon- (TRIF). MyD88-dependent signal transduction is
initiated through formation of a large oligomeric signaling
complex containing molecules of MyD88 and members of
the interleukin-1 receptor–associated kinase (IRAK) family,
termed the “myddosome” (5–7). Interactions of MyD88 with
the IRAKs are formed via common death domains (DDs),
whereas the effector functions of the IRAKs are mediated via
their central kinase domains. Myddosome formation promotes
IRAK4 autoactivation, which initially activates IRAK1 and, at
later time points, IRAK2 (8, 9). Putative binding motifs within
IRAK1 and IRAK2 allow for transient recruitment of the
E3 ubiquitin (Ub) ligase, TNF receptor–associated factor 6
(TRAF6), to the receptor complex tomediate its activation (10).
Once activated, TRAF6 is released into the cytosol, where it
triggers the IKK complex, leading to activation and nuclear
translocation of NF-B (11). In parallel, TRAF6 signaling also
activates IRF5 and triggers theMAPKpathway to activate AP-1
and cAMP-response element–binding protein (12). The acti-
vation of these transcription factors culminates in production
of potent pro-inflammatory cytokines and chemokines that
elicit an acute inflammatory response. Recently, Bryant and
colleagues (13) revealed that the kinetics ofmyddosome assem-
bly correlated with NF-B translocation and subsequent levels
of TNF cytokine produced.
IRAK4 is critical for transducing positive TLR responses in
both human andmurine cells (14–16). Similarly, reconstitution
of Irak4/mice andmurine cells with a kinase-dead version of
IRAK4 was unable to rescue the Irak4/ phenotype, demon-
strating that inmice, IRAK4 kinase activity is also vital (17–19).
Interestingly, whereas TLR responses in innate immune cells
from mice expressing kinase-dead IRAK4 were abolished,
IRAK4-independent signaling and T-cell receptor signaling
appeared intact (19). Likewise, several human cell populations
show differing dependences on the kinase activity of IRAK4 for
mediating TLR signaling (20–22). However, IRAK4 inhibitors
have been the intense focus for therapeutic intervention.
Although IRAK4 inhibitors have shown efficacy in murine
models of inflammation and autoimmunity, as well as in rare
MyD88-driven B-cell lymphomas in vitro (23–25), to date,
these encouraging results have not been recapitulated in
human inflammatory disease.
Despite the critical role myddosome formation plays in ini-
tiating TLR-induced signaling, the molecular mechanisms
of myddosome formation and subsequent proximal signaling
events remain poorly defined. Here, taking both genetic and
pharmacological approaches, we show that whereas inhibition
of IRAK4 kinase activity blocks TLR cytokine production, the
myddosome complex is actually more stable. Importantly, we
further found that the kinase activity of IRAK4 is dispensable
for TLR-mediatedNF-B signaling but essential for production
of inflammatory cytokines. These findingsmay explainwhy tar-
geting IRAK4 kinase activity has not been as successful as ini-
tially anticipated for treatment of inflammation.
Results
Activation of IRAK4 is an early MyD88-dependent TLR
signaling event
Loss of the IRAK1 signal by Western blotting is a reliable
indicator of early TLR signaling, which depends on the
upstream kinase activity of IRAK4 (26). IRAK4 activation
occurs via phosphorylation of Thr-345, Ser-346, and Thr-342
within its activation loop, with Thr-345 representing the pro-
totypical residue required for activation (9, 27, 28). Hence,
using a highly specific antibody to detect phosphorylation of
IRAK4 at Thr-345 and Ser-346 (20), we examined phosphory-
lated (P)-IRAK4, in addition to IRAK1 loss, by immunoblotting
following activation of a panel of TLR agonists in bone
marrow–derived macrophages (BMDMs). Activation of TLR4
(with LPS), TLR1/2 (with Pam3CysK4; P3C), or TLR9 (with
CpG DNA), all of which require the adaptor MyD88 to engage
downstream signaling, led to the appearance of P-IRAK4, with
LPS activation resulting in both the fastest kinetics and greatest
levels of IRAK4 activation (Fig. 1A). In contrast, a distinct
decrease in the protein signal of IRAK1 was observed following
stimulation of these TLRs (Fig. 1A). As a control, cells were also
stimulated with poly(I:C) to activate TLR3, which does not
require MyD88-IRAK4 to elicit downstream signaling, and as
expected did not result in IRAK4 phosphorylation or the loss of
IRAK1 (Fig. 1A). We next examined the kinetics of IRAK1 loss
and P-IRAK4 in greater detail by performing a time course fol-
lowing LPS stimulation. This revealed that LPS-induced phos-
phorylation of IRAK4 occurred from 5 to 120 min and most
robustly between 15 and 30 min, whereas loss of IRAK1 was
apparent from 10 min and continued to decrease for up to 4 h
(Fig. 1B). Phosphorylation of the subsequent signaling mole-
cules, p38 MAPK and NF-B p65, appeared to closely match
the kinetics of P-IRAK4 (Fig. 1B). Whereas the magnitude of
IRAK4 phosphorylation depended on the dose of LPS, its kinet-
ics did not (Fig. 1C). These data demonstrate that phosphory-
lation of IRAK4 is a specific and early MyD88-dependent event
following TLR activation.
Rapidmyddosome formation precedes gradual disassembly
The precise details surrounding myddosome formation and
disassembly remain elusive. We examined the kinetics of myd-
dosome assembly by immunoprecipitation (IP) experiments,
initially focusing on interactions between P-IRAK4 and the
adaptor MyD88 following acute LPS stimulation. Performing
P-IRAK4 IPs, we observed interactions with MyD88 as early as
5min following LPS stimulation (Fig. 2A). However, examining
longer time points, we found that whereas this interaction
remained stable at 30 min, by 2 h, it was no longer visible (Fig.
2B), which is most likely due to the loss of IRAK4 phosphory-
lation, as observed in whole-cell lysates (WCLs) (Figs. 1 (A and
B) and 2 (B and C)). We next performed reciprocal MyD88 IPs
and examined interactions with both P-IRAK4 and total
IRAK4. In line with Fig. 2B, P-IRAK4 interactions with MyD88
were visible at 30 min following LPS stimulation but lost by 2 h
(Fig. 2C). A weak interaction with IRAK1 was also observed at
30 min post-LPS treatment. Interestingly, the interaction
between MyD88 and total IRAK4 remained detectable for at
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least 2 h following LPS but was markedly reduced by 6 h (Fig.
2C).
To examine this further, we generated IRAK4 reporter
macrophages. Following production of retroviruses in HEK293T
cells (Fig. S1A), we reconstituted Irak4/ immortalized
BMDMs (iBMDMs) with WT IRAK4 fused to the fluorescent
protein mCitrine (mCit) (Fig. 1B). This allowed us to perform
specific IPs using the mCitrine tag (reactive to GFP antibodies)
to examine interactions of total IRAK4 in the myddosome
complex. To this end, we stimulatedWT IRAK4-mCit reporter
macrophages for up to 6 h with LPS, divided the resulting
whole-cell lysates, and performed simultaneous IPs for both
P-IRAK4 and total IRAK4 (via GFP). Consistent with the find-
ings from BMDMs (Fig. 2, B andC), P-IRAK4 interactions with
MyD88weremarkedly reduced by 2 h, whereas the interactions
between MyD88 and total IRAK4-mCit appeared stable for up
to 6 h following LPS stimulation (Fig. 2D).
Upon activation by LPS, TLR4 undergoes CD14-dependent
endocytosis to initiate the TRIF signaling pathway (29, 30).
Consistent with these reports, we also observed down-modula-
tion of surface TLR4 following LPS stimulation as determined
by flow cytometry (Fig. 2, E and F). These results indicate that
the loss of IRAK4 kinase activity is an active process that does
not require disassembly of themyddosome, which remains sta-
ble over a long period even following internalization of TLR4.
IRAK4 kinase activity is essential for MyD88-dependent TLR
cytokines
We next examined the effects of both pharmacological and
genetic inhibition of IRAK4 kinase activity on TLR-induced
cytokine mRNA expression and protein secretion frommurine
macrophages. First, primary BMDMs were pretreated for 30
min with a potent and highly selective IRAK4 inhibitor or with
DMSO alone as a control, before stimulation with several TLR
ligands eliciting MyD88-dependent signals for 4 h. IRAK4
kinase inhibition led to significant reductions in TLR-induced
Tnf, Il6, and Il1b mRNA expression (Fig. 3A), as well as dose-
dependent reductions in the secretion of TNF protein, with the
most pronounced decreases seen in response to stimulation of
TLR1/2 or TLR9 (Fig. 3B).
The genetic inhibition of IRAK4 kinase activity was tested by
comparing cytokine responses of Irak4/ iBMDMs reconsti-
tuted with mCit alone, WT IRAK4-mCit, or a kinase-dead
mutant form (K213A/K214A) of IRAK4 (IRAK4 KD) (see Fig.
S1). As in the case of pharmacological IRAK4 kinase inhibition,
macrophages expressing IRAK4 KD displayed significantly
decreased secretion of TNF following 4 h TLR stimulation
comparedwith theWT IRAK4 counterparts, whereas Irak4/
iBMDMs expressing mCit alone were mostly unresponsive
(Fig. 3C). As a control, we showed that the reporters produce
similar levels of TNF via activation of a MyD88-independent
pathway using themurine STING ligand, 10-carboxymethyl-9-
acridanone (CMA), demonstrating no intrinsic defects in the
different cell populations (Fig. 3C). It should be noted that the
levels of TNF secreted by the IRAK4-mCit iBMDMs were
greater than those from primary BMDMs, most likely due to
higher IRAK4-mCit expression levels than those seen for
endogenous IRAK4 (see Fig. S1). In both cases, cells stimulated
with LPS only showed a reduced dependence on IRAK4 kinase
activity, which is attributed to TLR4-mediated initiation of the
TRIF signaling pathway in addition to those dependent on
MyD88 and IRAK4. These data demonstrate that the kinase
activity of IRAK4 is critical for MyD88-dependent TLR-in-
duced cytokine mRNA and protein production in mouse
macrophages.
Inhibition of IRAK4 kinase activity stabilizesmyddosome
complexes
We found that treatment of BMDMs with a specific IRAK4
kinase inhibitor significantly inhibited TLR-induced cytokines
(Fig. 3, A and B). However, our finding that myddosome inter-
actions are stable following dephosphorylation of IRAK4 (Fig.
2, C and D), together with published observations that IRAK4
kinase activity is not required for interactions with MyD88,
IRAK1, or IRAK2 (19, 31), strongly suggested that the kinase
Figure 1.MyD88-dependent TLR signaling activates IRAK1 and IRAK4.A,
BMDMs were left untreated or stimulated with a panel of synthetic TLR
ligands for up to 2 h: 10 g/ml poly(I:C) (pI:C-TLR3); 1 g/ml LPS (TLR4); 200
ng/ml Pam3CysK4 (P3C-TLR1/2); or 0.1 M CpG DNA 1826 (TLR9). WCLs were
subjected to immunoblotting for IRAK1, P-IRAK4, and actin as a loading con-
trol. The data presented are representative of three independent experi-
ments. B, BMDMs were left untreated or stimulated with 1 g/ml LPS from 5
min up to 4 h. WCLs were subjected to immunoblotting for IRAK1, P-IRAK4,
P-p38MAPK, NF-B P-p65, and actin as a loading control. The data presented
are representative of two independent experiments. C, BMDMs were left
untreated or stimulatedwith either 200 ng/ml or 1g/ml LPS from10min up
to 2 h.WCLswere subjected to immunoblotting for IRAK1, P-IRAK4, and actin
as a loading control. The data presented are representative of three indepen-
dent experiments.
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activity of IRAK4 is dispensable for myddosome formation.
Therefore, we specifically examined the effects of IRAK4 kinase
inhibition on the stability of the myddosome complex. In
whole-cell lysates, we noted that pretreatment with the IRAK4
inhibitor blocked detectable LPS-induced P-IRAK4 and
reduced the decrease of IRAK1 levels, demonstrating efficacy of
the inhibitor (Fig. 4A). Surprisingly, however, we found that
pretreatment with the IRAK4 kinase inhibitor led to a robust
increase in the interactions between MyD88 and IRAK4
following LPS stimulation in both primary BMDMs and WT
iBMDMs when examined by MyD88 IP (Fig. 4, A and B). We
further interrogated the effect of inhibiting IRAK4 kinase activ-
ity onmyddosomes formed downstream of other TLRs. Similar
to TLR4-induced responses, interactions between MyD88 and
IRAK4 were greatly increased in response to TLR1/2 or TLR9
activation in BMDMs pretreated with the IRAK4 inhibitor (Fig.
4C). Aside fromMyD88 and IRAK4, the proposed myddosome
complex also comprises IRAK1 (and/or IRAK2) (6). Interest-
ingly, under conditions of IRAK4 kinase inhibition, we also
observed IRAK1 interaction with MyD88, which was almost
undetectable in macrophages pretreated with DMSO (Fig. 4,
A–C). This may be explained by the increased levels of IRAK1
detectable in WCLs following IRAK4 kinase inhibition.
To complement these results, Irak4/ iBMDMs expressing
IRAK4-mCit were tested under the same experimental condi-
tions followed by GFP IP, which similarly led to increased com-
plex formation between MyD88 and IRAK4-mCit, albeit less
than in WT macrophages (Fig. 4D). Finally, we examined the
effect of genetic inhibition of IRAK4 kinase activity on myddo-
some formation using the IRAK4 reporter macrophages gener-
ated (Fig. S1). In this case, Irak4/ iBMDMs reconstituted
with either mCit alone, IRAK4-mCit, or IRAK KD-mCit were
treated for 30 min with LPS and subjected to GFP IP. This
approach demonstrated that, like chemical inhibition of
IRAK4, genetic ablation of IRAK4 kinase activity also results in
increased levels of MyD88 complexed with IRAK4 (Fig. 4E). As
expected, the Irak4/ control cells expressing mCit alone
showed no interaction with MyD88.
Wenext examinedwhether inhibition of IRAK4 kinase activ-
ity increased the stability of the myddosome over time. To this
Figure 2. Myddosome complexes form rapidly but are stable following the loss of P-IRAK4. BMDMs were left untreated or stimulated with 1 g/ml LPS
for 5, 10, and 15 min (A) or 30 min and 2 h (B). A and B, WCLs were then subjected to P-IRAK4 IP followed by MyD88 immunoblotting or directly subjected to
immunoblotting for IRAK-1, P-IRAK4, and MyD88, which also served as a loading control. The data presented are representative of three independent
experiments. C, BMDMs were left untreated or stimulated with 1 g/ml LPS for 30 min, 2 h, or 6 h. WCLs were then subjected to MyD88 IP, followed by
immunoblotting for P-IRAK4, IRAK4, IRAK1, and MyD88, or directly subjected to immunoblotting with the same antibodies. The data presented are represen-
tative of three independent experiments. D, Irak4/ iBMDMs expressing IRAK4-mCitrine were generated as described under “Experimental procedures.”
These cells were left untreated or stimulated with 1 g/ml LPS for 30 min, 2 h, 4 h, or 6 h before WCLs were divided evenly and subjected to either P-IRAK4 IP
or GFP IP followedby immunoblotting forMyD88 andGFP.WCLswere also directly subjected to immunoblotting for IRAK1, GFP, P-p38MAPK, andMyD88. The
data presented are representative of two independent experiments. E, BMDMs were left untreated (UT) or stimulated with 1 g/ml LPS for 2 or 6 h before
stainingwith an antibody against the extracellular region of TLR4 and subjected to flow cytometric analysis to determine the level of TLR4 surface expression.
Tlr4/ iBMDMswere also stained as a control. One representative experiment is presented. F, TLR4 surface expression was then quantified by examining the
geometric mean of stained cells. Data are presented as the mean  S.E. (error bars) (untreated versus LPS: **, p  0.01; ***, p  0.001) combined from four
individual experiments.
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end,we pretreatedBMDMswithDMSOor the IRAK4 inhibitor
and examinedmyddosome interactions 2 and 4 h following LPS
stimulation. Similar to Fig. 2C, in DMSO pretreated cells, LPS
stimulation induced the interaction of MyD88 and IRAK4 at
2 h, which was all but lost by 4 h. In contrast, cells pretreated
with the IRAK4 inhibitor showed increased interaction at 2 h
and continued association at 4 h (Fig. 4F). Together, these data
demonstrate that in the absence of IRAK4 kinase activity,
MyD88 interacts more strongly with IRAK4 and for longer,
thus constituting a considerably more stable myddosome com-
plex. This strongly suggests that IRAK4 plays a significant scaf-
fold function in TLR signaling, independent of its kinase
activity.
The rapid loss of IRAK1 following TLR activation was ini-
tially attributed to proteasomal degradation (32–34). However,
recent studies have shown that following activation by IRAK4,
IRAK1 actually undergoes significant phosphorylation and
ubiquitination events resulting in slower-migrating protein
species that are not reactive withmost IRAK1 antibodies unless
protein lysates are subjected to phosphatase and deubiquitinase
treatment (35, 36). As we were only able to clearly observe
IRAK1 complexed within the myddosome following treatment
of cells with the IRAK4 inhibitor, we generated a reporter cell
system in which we could examine activated IRAK1 expression
by immunoblotting. To do this, we stably expressed IRAK1
fused to the fluorescent protein, mCerulean (mCer), in WT
iBMDMs, enabling us to monitor the signal of both the endog-
enous IRAK1 and IRAK1-mCer (reactive to GFP antibodies).
We treated these IRAK1 reporter cells with LPS for up to 4 h
and observed no loss of the mCer signal as examined by flow
cytometry (Fig. 5A), suggesting that IRAK1-mCer was not
degraded within this time frame. Using an antibody against
IRAK1, we next examined the effects of LPS treatment on the
IRAK1 reporter cells, finding that whereas the signal for endog-
enous IRAK1 rapidly disappeared after 30 min, the larger
IRAK1-mCer species remained detectable up to 4 h post-stim-
ulation (Fig. 5B). Probing with a GFP antibody confirmed that
IRAK1-mCer is detectable over time and undergoes post-trans-
lationalmodifications, as observed by significant smearing con-
sistent with the altered molecular weight following LPS treat-
ment (Fig. 5B). To test that this smearing indeed represents
IRAK1 activation, we pretreated the IRAK1 reporter cells with
the IRAK4 inhibitor or DMSO before stimulating the cells with
LPS. In the presence of the IRAK4 inhibitor, the disappearance
Figure 3. IRAK4 kinase activity is critical for MyD88-dependent cytokine production. A, BMDMs were pretreated with either DMSO or a 20 M concen-
tration of a selective IRAK4 inhibitor (I4 inhb) for 30min. Cellswere then left untreated (UT) or stimulatedwith either 1g/ml LPS, 500 ng/ml P3C, or 0.5MCpG
DNA1826 for a further 4 h. Cells were then lysed for RNA isolation andmRNA analysis by qPCR. Data are presented as themean S.E. (error bars) (DMSO versus
I4 inhb: *, p 0.05; **, p 0.01) combined from three independent experiments. B, BMDMswere pretreatedwith either DMSOor 0.2–20M I4 inhb for 30min.
Cells were then left untreated (UT) or stimulated with either 1 g/ml LPS, 500 ng/ml P3C, or 0.5 M CpG DNA 1826 for a further 4 h. Supernatants were then
collected and subjected to ELISA to determine the levels of secreted TNF. Data are presented as themean S.E. (DMSO versus I4 inhb: ns, not significant; *, p
0.05; **, p 0.01; ***, p 0.001) combined from four individual experiments. C, Irak4/ iBMDMs expressing either mCitrine alone, IRAK4-mCitrine, or IRAK4
KD-mCitrine were stimulated with 1 g/ml LPS, 500 ng/ml P3C, 0.5 M CpG DNA 1826, or 500 g/ml CMA (a murine STING ligand) for 4 h. Supernatants were
then collected and subjected to ELISA to determine the levels of secreted TNF. Data are presented as themean S.E. (IRAK4-mCit versus IRAK4KD-mCit:ns, not
significant; *, p 0.05; ***, p 0.001) combined from three individual experiments.
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of the endogenous IRAK1 signal was reduced, demonstrating
efficacy of the inhibitor to prevent IRAK1 activation, whereas
the smearing seen in the GFP immunoblot was significantly
decreased, demonstrating that IRAK4 induces IRAK1 modifi-
cations (Fig. 5C). We then examined myddosome formation in
the IRAK1-mCer reporter macrophages and found that follow-
ing GFP IP, we could observe interactions of MyD88 with
IRAK1-mCer (Fig. 5D). Finally, we examined the effects of
IRAK4 kinase inhibition on interactions of IRAK1-mCer and
MyD88. Consistent with our previous results, we observed that
pretreatment of cells with the IRAK4 inhibitor resulted in
increased binding of MyD88 to IRAK1-mCer following LPS
stimulation (Fig. 5E). These data further demonstrate increased
stabilization of the myddosome complex in the absence of
IRAK4 kinase activity by increasing the association of IRAK1
with MyD88.
The dual role of IRAK4 in themyddosome
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IRAK4 kinase activity is dispensable for NF-B andMAPK
activation downstream of TLR activation
We have found that inhibition of IRAK4 can strongly inhibit
MyD88-dependent TLR cytokine production (Fig. 3) while
unexpectedly stabilizing the myddosome complex (Figs. 4 and
5). To further identify the mechanisms underlying ablation of
TLR cytokine responses by IRAK4 kinase inhibition, we exam-
ined its effects on signalingmolecules downstream of TLR acti-
vation. First, we pretreated BMDMs with DMSO or the IRAK4
inhibitor before stimulating cells for 30–90min with LPS to elicit
TLR4 activation. This revealed that although BMDMs pretreated
with the IRAK4 inhibitor showed a loss of P-IRAK4, only aminor
effect was seen on IRAK1 levels and the activation of both NF-B
p65 and p38 MAPK (Fig. 6A). We next examined TLR1/2, an
entirely MyD88-dependent pathway to account for any compen-
satory effects of TRIF signaling during TLR4 responses. Again,
whereas P-IRAK4 was abolished, we only observed minor effects
on the other TLR signaling molecules examined (Fig. 6B).
We then examined the nuclear translocation of NF-B p65
following IRAK4 kinase inhibition. Similar to the phosphoryla-
tion of NF-B p65 (Fig. 6B), IRAK4 kinase inhibition modestly
reduced TLR1/2-induced NF-B p65 translocation into the
nucleus; however, this responsewas not totally ablated (Fig. 6,C
and D). These results demonstrate that specific inhibition of
IRAK4 activity has minimal effects on the activation of NF-B
and MAPK signaling, as well as NF-B p65 nuclear transloca-
tion downstreamof TLR activation. Importantly, these findings
are supported by recentwork demonstrating that the kinetics of
NF-B translocation are a critical determinant for levels of TNF
cytokine production (13).
Figure 4. IRAK4 kinase inhibition stabilizes TLR-inducedmyddosome interactions. A, BMDMs were pretreated with either DMSO or 20 M I4 inhb for 30
min. Cells were then left untreated or stimulated with 1 g/ml LPS for a further 30 min. WCLs were then subjected to MyD88 IP followed by immunoblotting
for IRAK4, IRAK1, P-IRAK4, and MyD88 or directly subjected to immunoblotting with the same antibodies. MyD88 immunoblotting also acted as a loading
control. The data presented are representative of three independent experiments. B, WT iBMDMswere treated as in A, beforeWCLs were subjected toMyD88
IP followed by immunoblotting for IRAK4, IRAK1, and MyD88 or directly subjected to immunoblotting with the same antibodies. The data presented are
representative of three independent experiments. C, BMDMs were pretreated with either DMSO or 20M I4 inhb for 30 min. Cells were then left untreated or
stimulated with either 500 ng/ml P3C or 0.5 M CpG DNA 1826 for a further 30 min. WCLs were then subjected to MyD88 IP followed by immunoblotting for
IRAK4, IRAK1, P-IRAK4, andMyD88 or directly subjected to immunoblottingwith the same antibodies. MyD88 immunoblotting also acted as a loading control.
The data presented are representative of three independent experiments. D, Irak4/ iBMDMs expressing IRAK4-mCitrine were treated as in A before WCLs
were subjected to GFP IP, followed by immunoblotting for MyD88 and GFP, or directly subjected to immunoblotting for P-IRAK4, IRAK1, GFP, andMyD88. The
data presented are representative of three independent experiments. E, Irak4/ iBMDMs expressing either mCitrine alone, IRAK4-mCitrine, or IRAK4 KD-
mCitrine were stimulated with 1 g/ml LPS for 30 min before WCLs were subjected to GFP IP followed by immunoblotting for MyD88 and GFP or directly
subjected to immunoblotting with the same antibodies. The data presented are representative of four independent experiments. F, BMDMs were pretreated
with either DMSO or 20M I4 inhb for 30min. Cells were then left untreated or stimulatedwith 1g/ml LPS for a further 2 or 4 h. WCLs were then subjected to
MyD88 IP, followed by immunoblotting for IRAK4, IRAK1, P-IRAK4, and MyD88, or directly subjected to immunoblotting with the same antibodies. MyD88
immunoblotting also acted as a loading control. The data presented are representative of three independent experiments.
Figure 5. Examination of IRAK1 inmyddosome interactions. A and B, WT iBMDMs expressing IRAK1-mCeruleanwere left untreated (UT) or stimulatedwith
1g/ml LPS for 2or 4h.A, cellswere collectedand subjected to flowcytometric analysis todetermine levels ofmCerulean fluorescence.WT iBMDMsalonewere
also included as a negative control. Data are representative of three independent experiments. B, WCLswere subjected to immunoblotting for IRAK1, GFP, and
actin as a loading control. Endogenous IRAK1 and IRAK1-mCer are indicatedwith arrows, whereas smears inGFP immunoblots representing ubiquitinated and
phosphorylated IRAK1 are indicated with a line. Data presented are representative of three independent experiments. C, WT iBMDMs expressing IRAK1-
mCerulean were pretreated with either DMSO or 20 M I4 inhb for 30 min. Cells were then left untreated or stimulated with 1 g/ml LPS for 2 h. WCLs were
subjected to immunoblotting for IRAK1, GFP, P-IRAK4, and actin as a loading control. Data presented are representative of three independent experiments.D,
WT iBMDMs expressing IRAK1-mCerulean were left untreated or stimulated with 1g/ml LPS for 30 min or 2 h. WCLs were then subjected to GFP IP followed
by immunoblotting forMyD88andGFPordirectly subjected to immunoblottingwith the sameantibodies.MyD88 inWCLs also servedas a loading control. The
data presented are representative of three independent experiments. E, WT iBMDMs expressing IRAK1-mCeruleanwere pretreatedwith either DMSOor 20M
I4 inhb for 30 min. Cells were then left untreated or stimulated with 1 g/ml LPS for a further 30 min. WCLs were then subjected to GFP IP followed by
immunoblotting with MyD88 and GFP or directly subjected to immunoblotting for GFP, P-IRAK4, and MyD88. The data presented are representative of four
independent experiments.
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Discussion
The molecular integrity of the myddosome is critically
required to facilitate downstream TLR signal transduction.
However, to date, the molecular mechanisms controlling as-
sembly, stability, kinetics, and composition of myddosome sig-
naling complexes remain poorly understood. Here, we isolated
myddosome complexes from TLR-activated primary mouse
macrophages and from IRAK reporter macrophages, demon-
strating rapid assembly and slow disassembly kinetics. To our
knowledge, this is the first full examination of the kinetics of the
myddosome.
IRAK4 is thought to become activated via trans-autophos-
phorylation following incorporation into the myddosome
structure (9). Hence, our novel approach of isolating myddo-
some complexes in primary mouse macrophages via P-IRAK4
IP represents interactions within the active structure, whereas
reciprocal IPs of MyD88 allowed us to examine the total con-
stituents of the myddosome, even in the absence of P-IRAK4.
This was further explored via generation of IRAK4-mCit and
IRAK1-mCer reporter macrophages to examine interaction
with total IRAK4 or IRAK1, respectively, via GFP IPs. Interest-
ingly, these approaches led us to observe that whereas P-IRAK4
appears to be lost around 30 min post-LPS stimulation, the
interactions of total IRAK4, MyD88, and IRAK1 are stable for
up to 2 h. Collectively, these data show that IRAK4 kinase func-
tion is actively shut off within the myddosome complex. Addi-
tionally, this demonstrates that IRAK4 dephosphorylation
appears to occur independent of myddosome disassembly and
is therefore unlikely to initiate this process. Together with our
findings that IRAK4 inhibition or expression of a kinase-dead
IRAK4 failed to inhibit myddosome formation, these data sug-
gest that the catalytic activity of IRAK4 is dispensable for both
assembly and disassembly of the myddosome.
Utilizing single-molecule fluorescence microscopy of GFP-
tagged MyD88 in Myd88/ iBMDMs, Bryant and colleagues
showed that MyD88 rapidly forms membrane-bound macro-
molecular complexes, which are removed from the cell surface
within about 10 min following LPS stimulation (13). LPS stim-
ulation did not induce formation of TLR4 oligomers on the cell
surface, suggesting a stoichiometric mismatch between acti-
vated receptor complexes and oligomeric myddosomes (13).
These observations from live single cells, together with our
Figure 6. IRAK4 kinase activity is dispensable for NF-B andMAPK activation downstreamof TLRs. A–C, BMDMswere pretreatedwith either DMSO or a
20 M concentration of a selective I4 inhb for 30 min. Cells were then left untreated or stimulated with 1 g/ml LPS (A) or 500 ng/ml P3C (B) for an additional
30, 60, or 90 min. WCLs were then subjected to immunoblotting for IRAK1, P-IRAK4, NF-B P-p65, P-p38 MAPK, and actin as a loading control. Data presented
are representativeof at least three independent experiments.C, cellswere then left untreated (UT) or stimulatedwith500ng/mlP3C for anadditional 4hbefore
fixation and staining with an NF-B P-p65 antibody, followed by a specific secondary antibody conjugated to an Alexa-488 fluorophore. Samples were then
examined by confocal microscopy. Representative images are presented from three biological replicates. Scale bar, 10 m. D, NF-B P-p65 nuclear transloca-
tion was then quantified by examining the mean fluorescence intensity of the Alexa-488 signal in cell nuclei. Nuclear intensity was made relative to DMSO-
untreated samples and presented as themean S.E. (error bars) (DMSO versus IRAK4 inhb: *, p 0.05; **, p 0.01) combined fromBMDMs derived from three
individual mice (biological replicates).
The dual role of IRAK4 in themyddosome
15202 J. Biol. Chem. (2018) 293(39) 15195–15207
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on O
ctober 8, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
findings that stable myddosome interactions can be detected
for up to 2 h from LPS-stimulated BMDMs using biochemical
analysis of whole cellular lysates, suggest that following an
initial TIR-driven process mediated by activation of surface
TLR4–MD-2 receptor complexes, myddosomes may detach
from the intracellular domains of TLR4 and be released into the
cytosol. This idea is strengthened by observations that a specific
de novomutation in the TIR domain ofMyD88 (L265P) leads to
constitutive myddosome complexes driving aberrant NF-B
activation and inflammation in a number of B-cell human lym-
phomas (23), which to date has not been shown to be dependent
on TIR domains from TLRs.
Surprisingly, we found that a loss of IRAK4 activity by either
chemical inhibition or genetic manipulation resulted in a sig-
nificantly more stable myddosome structure. This increase in
stability is suggestive of a prominent protein scaffold role of
IRAK4, independent of its kinase activity, in which IRAK4
interacts withMyD88 and IRAK1, tethering them together into
the myddosome complex. Indeed, several earlier reports noted
higher-affinity interactions ofMyD88, TRAF6, and IRAKs with
kinase-inactive versions of IRAK1 or IRAK4 in overexpression
studies (26, 31, 37, 38). Additionally, using luminescence-based
mammalian interactomemapping (LUMIER), a technique ena-
bling examination of protein–protein interactions (39), it was
shown that the association of MyD88 with IRAK4 KD is signif-
icantly greater (5-fold) compared with that of WT IRAK4
(40). The phosphorylation of IRAK proteins may reduce intrin-
sic protein–protein binding affinitieswithin themyddosomeby
facilitating changes in surface-binding interfaces within their
respective kinase domains or changes in their overall protein
conformation. This is supported by the observation that de-
phosphorylation of full-length IRAK4 in solution with -phos-
phatase leads to formation of stable dimeric complexes,
whereastheadditionofATPinducesautophosphorylatedmono-
meric IRAK4 (9). Furthermore, the same was true when the
kinase domain of IRAK4 alone was examined (9). This is highly
suggestive that the kinase domain of IRAK4 plays a critical role
in stabilizing IRAK4dimers and likely themyddosome complex
itself, independent of the DD–DD interactions that organize
the primary complex formation.
We identified that the kinase activity of IRAK4 is critical for
MyD88-dependent cytokine production but is unnecessary for
myddosome formation, activation and nuclear translocation of
NF-Bp65, and activation of theMAPKpathway. Interestingly,
like IRAK4 kinase activity, the enzymatic function of TRAF6
was shown to be essential for cytokine production but play only
a minor role in the activation of NF-B and MAPK signaling
molecules following TLR activation (41). These paradoxical
observations are made clearer by recent findings from human
monocytes, where the kinase activity of IRAK4 was critical for
TLR7/8 cytokine responses via specific control of nuclear
translocation of IRF5 but redundant for NF-B (42). These
data, together with our observation, strongly support a
model in which IRAK4 plays a dual role in myddosome for-
mation and TLR signaling in macrophages. Primarily, IRAK4
itself is essential as a scaffold molecule during the assembly
of the myddosome, facilitating NF-B and MAPK signaling
(Fig. 7A). Although dispensable for NF-B activation, the
kinase activity of IRAK4 is specifically required to elicit an
inflammatory cytokine response (Fig. 7B), which may be
mediated via activation of IRAK1/2 and the E3 Ub ligase
activity of TRAF6.
For some time, IRAK4 kinase inhibitors have been an attrac-
tive target for therapeutic use in chronic inflammatory and
autoimmune diseases. Interestingly, IRAK4 kinase inhibition
has selective effects on cytokine responses from differing
human cell populations (20). Our findings that IRAK4 inhibi-
tion maintains the scaffolding function of IRAK4 for myd-
dosome-dependent NF-B and MAPK activation may help
to explain these observations. Although IRAK4 kinase inhib-
itors have shown great efficacy in various murine inflamma-
tory disease models (24, 43), it is yet to be determined
whether this will translate to positive outcomes in human
conditions. Our findings may help explain why, to date, tar-
geting IRAK4 kinase activity has not been more successful.
Furthermore, we highlight that targeting the scaffold func-
tion of IRAK4 may be an attractive alternative for therapeu-
tic inhibition.
Experimental procedures
Reagents
Reagents includedwere as follows: LPS fromEscherichia coli,
serotype EH100 (Ra)-TLR grade (Enzo Life Sciences); P3C,
1826 CpG DNA, high-molecular weight poly(I:C) (Invivogen);
DMSO, CMA, also known as 9-oxo-10(9H)-acridineacetic acid
(Sigma-Aldrich); IRAK4 inhibitor, also known as PF-06426779
or compound 38 (Pfizer) (44).
Cell culture
The use ofmice in this study for generating primary BMDMs
was approved by the Walter and Eliza Hall Institute Animal
Ethics Committee. BMDMs were obtained by culturing bone
marrow cells harvested from 6–8-week-oldWTC57BL/6mice
in Dulbeccos modified Eagles medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS; Sigma-Aldrich), 100
units/ml penicillin, 100 g/ml streptomycin, and 20% L929
conditioned medium at 37 °C in a humidified atmosphere with
10% CO2. Six days later, adherent BMDMs were harvested and
plated for experiments. HEK293T cells and iBMDMs (WT,
Irak4/, and Tlr4/) (45) were maintained in DMEM with
10% FBS, 100 units/ml penicillin, and 100 g/ml streptomycin
at 37 °C in a humidified atmosphere with 10% CO2.
Generation of IRAK reporter macrophages
Retroviral plasmids expressing murine IRAK4 (pR-IRAK4-
mCitrine) or a KD version of IRAK4 (pR-IRAK4 KDK213A/K214A-
mCitrine) fused to mCitrine at the C-terminus were
generated as described previously (16). The pRH-IRAK1-
mCerulean retroviral plasmid expressing murine IRAK1-
mCerulean was generated by amplifying murine IRAK1 from
the pEF-V5-IRAK1 expression vector (31) using specific
primers (forward, 5-tttggatccATGGCCGGGGGGCCGG-3;
reverse, 5-aaactcgagGCTCTGGAATTCATCACTTTCTTC-
AGGTC-3) before the resultant PCR product was digested
with BamHI and XhoI and cloned in-frame into the corre-
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sponding sites of the pRH-mCerulean retroviral vector.
Irak4/ iBMDMs expressing either mCitrine alone, IRAK4-
mCitrine, or IRAK4 KD-mCitrine were generated by retroviral
transduction with the pR-mCitrine, pR-IRAK4-mCitrine, or
pR-IRAK4 KDK213A/K214A-mCitrine plasmids, respectively.
Following retroviral transduction, cells were then sorted based
on positive expression of mCitrine to approximately the same
levels between the three cell lines. WT iBMDMs expressing
murine IRAK1-mCerulean were generated by retroviral trans-
duction with the pRH-IRAK1-mCerulean plasmid. In this case,
positive cells were selected via antibiotic treatment with 600
g/ml hygromycin (Invivogen) for at least 7 days. All retroviral
transduction and selection was performed using a well-de-
scribed protocol (46).
CytokinemRNA analysis by quantitative PCR
RNAwas isolated using the EZ-10 DNAaway RNAMiniprep
Kit (Bio Basic) according to the manufacturer’s protocol before
cDNA synthesis. Quantitative real-time PCR (qPCR) was per-
formed on cDNA using the Maxima SYBR Green/ROX qPCR
Master Mix (Thermo Scientific) on a Viia 7 real-time PCR sys-
tem (Thermo Scientific). Primer sequences used were as
described previously (47). Expression of target genes was nor-
malized to respective housekeeping genes. Cytokine mRNA
expression data are presented as mean S.E., from three com-
bined experiments.
Measurement of secreted cytokines by ELISA
Levels of murine TNF cytokine in cell culture supernatants
were measured by ELISA (Thermo Scientific) as per the man-
ufacturer’s instructions. ELISA data are presented as mean 
S.E., from at least three combined experiments.
Generation of whole-cell lysates
For immunoprecipitation experiments,10 106 iBMDMs
or 20 106 BMDMswere lysed on ice for 30min with 750l of
1Nonidet P-40 buffer (1%Nonidet P-40, 20mMTris-HCl, pH
7.4, 150 mM NaCl, 1 mM EGTA, 10% glycerol, 10 mM NaPPi, 5
mMNaF, and 1 mMNa3VO4) supplemented with 1 mM phenyl-
methylsulfonyl fluoride and cOmplete protease inhibitors
(Roche Applied Science). For immunoblotting experiments,
1.0 106 iBMDMs or BMDMs were lysed on ice with 120 l
of 1 radioimmune precipitation buffer (20 mM Tris-HCl, pH
7.4, 150mMNaCl, 1 mM EDTA, 1% Triton X-100, 10% glycerol,
0.1% SDS, 0.5% deoxycholate, 10 mM NaPPi, 5 mM NaF, and 1
mM Na3VO4) supplemented with 1 mM phenylmethylsulfonyl
fluoride and cOmplete protease inhibitors (Roche Applied Sci-
ence).Whole-cell lysateswere subsequently clarified by centrif-
ugation at 13,000 g for 10 min at 4 °C.
Immunoblotting
For immunoblotting experiments, 60 l of whole-cell lysate
were diluted in 20l of 4 reducing SDS-PAGE sample loading
Figure 7. A model of MyD88-dependent TLR signaling events in the presence and absence of IRAK4 kinase activity. A, activation of TLR dimers at
membranes leads to rapid recruitmentof theTIR adaptorMyD88and theorderedassemblyof anoligomeric signalingplatform termed themyddosome,which
comprises four layers: 2 molecules of MyD88, 4 molecules of MyD88, 4 molecules of IRAK4, and 4 molecules of IRAK1/2. Myddosome formation
facilitates IRAK4autophosphorylation and subsequentphosphorylationof IRAK1. The E3Ub ligase, TRAF6, is then thought to simultaneously activate signaling
pathways leading to the transcriptional activity of NF-B, AP-1 and cAMP-response element–binding protein (via the MAPK pathway), and IRF5, which act in
concert for the production of inflammatory cytokines. B, in the absence of IRAK4 kinase activity, the myddosome assembles into a more stable complex
following TLR activation. The activation of NF-B and MAPK signaling is only moderately affected by IRAK4 inhibition.
The dual role of IRAK4 in themyddosome
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buffer (1.25% SDS, 12.5% glycerol, 62.5 mM Tris-HCl, pH 6.8,
0.005% bromphenol blue, 50 mM DTT) and heated to 95 °C for
10min before 20–35l was run onNovex 4–12% precast SDS-
polyacrylamide gels (Thermo Scientific) with MES running
buffer (ThermoScientific). Separated proteinswere transferred
onto polyvinylidene difluoride membranes (Millipore) and
blocked in 5% skim milk powder in PBS with Tween 20 before
overnight incubation with specific primary antibodies: anti-
MyD88 (R&D Systems; AF3109, 1:1000), anti-P-IRAK4 Thr-
345/Ser-346 (Pfizer (20), 1:500), anti-IRAK4 (Thermo Scien-
tific; clone 2H9, MA5-15883, 1:500), anti-IRAK1 (Santa Cruz
Biotechnology, Inc.; clone H-273, sc-7883, 1:1000 (discontin-
ued)), anti-P-p65 Ser-536 (Cell Signaling Technology; clone
93H1, 3033, 1:500), anti-P-p38 Thr-180/Tyr-182 (Cell Signal-
ing Technology; 9211, 1:1000), anti-GFP (Thermo Scientific;
A-11122, 1:1000), or anti-actin (Santa Cruz Biotechnology;
clone I-19, sc-1616, 1:2000 (discontinued)). Membranes were
then washed and incubated with appropriate secondary anti-
bodies, and immunoreactivity was imaged using the ChemiDoc
Touch Imaging System (Bio-Rad).
Isolation ofmyddosome complexes by immunoprecipitation
Following preparation of samples for immunoblotting, 1–2
g of primary antibody was added to the remaining whole-cell
lysate: anti-MyD88 (R&D Systems; AF3109), anti-P-IRAK4
Thr-345/Ser-346 (Pfizer (20)), or anti-GFP (Thermo Scientific;
clone E36, A-11120). Samples were then incubated at 4 °C for
up to 2 h (or overnight) on a rotator before 50 l of Dynabeads
ProteinA (Thermo Scientific; 10002D) orDynabeads ProteinG
(Thermo Scientific; 10004D) were added. Samples were then
incubated once more at 4 °C for up to 2 h on a rotator before
beads were extensively washed with lysis buffer using a
DynaMag-2magnet (Thermo Scientific; 12321D), and proteins
were eluted by the addition of 35l of 2 reducing SDS-PAGE
sample loading buffer (2.5% SDS, 25% glycerol, 125 mM Tris-
HCl, pH 6.8, 0.01% bromphenol blue, 100 mM DTT) and heat-
ing at 95 °C for 10 min. Samples were then subjected to immu-
noblotting as described above.
Measuring TLR4 surface expression by flow cytometry
Approximately 1.0 106 BMDMs orTlr4/ iBMDMswere
harvested on ice using PBS containing 2% FBS. Nonspecific Fc
receptor binding sites were blocked using an anti-mouse
CD16/32 antibody (BioLegend; clone 93, 101301, 1:400) before
cells were stained with a PE/Cy7 anti-mouse CD284 (TLR4)
antibody (BioLegend; clone SA15-21, 145408, 1:100), and sam-
ples were analyzed on an LSR Fortessa cell analyzer (BD
Biosciences).
Immunofluorescence (IF) of NF-B p65 nuclear translocation
Eight-well -slides (Ibidi) were coated with poly-L-lysine
(Sigma) before BMDMs were seeded at 2  105 cells/well and
experiments were performed. Cells were then fixed with 4%
paraformaldehyde for 30 min, before blocking and permeabi-
lizing cells (IF buffer: PBS, 10% FBS, 0.5% Triton X-100) for 1 h,
before staining with a rabbit monoclonal anti-NF-B p65 (Cell
Signaling Technology; clone C22B4, 4764, 1:100) overnight at
4 °C. Cells were then stained with a secondary donkey anti-
rabbit Alexa-488 antibody (Thermo Scientific; R37118, 1:1000)
for 1 h at room temperature, before nuclear staining with 4,6-
diamidino-2-phenylindole (1 M) for 5–10 min. After each
step, cells were washed 2–3 times with IF buffer or PBS. Cells
were imaged using a Zeiss LSM 780 confocal microscope; 2 2
tile scans were obtained for each experimental condition using
a 40 oil objective with Immersol 518 F (Zeiss) and acquired
with ZEN 2012 version 8.1 software (Zeiss). Images were gen-
erated as tagged image bitmap files (TIFF) using FIJI software.
Quantification of nuclear NF-B p65 was performed using FIJI
software by overlaying nuclei identified with 4,6-diamidino-2-
phenylindole staining (not shown) onto the Alexa-488 channel
before measurement of mean fluorescent intensity within each
nucleus.
Statistical analysis
Analyses were performed with Prism (GraphPad Software,
Inc.), and data are typically presented as themean S.E., where
ap value 0.05was considered significant, as determined by an
unpaired two-tailed Student’s t test.
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